questionText: To ask the Secretary of State for Health and Social Care, if he will take steps to ensure NHS patients with Mantle Cell Lymphoma will continue to be able to receive the CAR-T treatment Tecartus after it has exited the Cancer Drugs Fund.
answerText: Decisions on whether new medicines should be routinely funded by the National Health Service in England are made by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of their costs and benefits. NICE is currently r...
heading: Blood Cancer: Medical Treatments